The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
News|Articles|September 1, 2001
- Pharmaceutical Technology-09-01-2001
- Volume 2001 Supplement
- Issue 3
Compendium of Pharmaceutical Excipients for Vaginal Formulations
To aid the fomulation scientist in selecting the optimal excipients for the preparation of vaginal products, the authors have compiled a list of all presently available vaginal excipients, including their functional categories and regulatory status.
Advertisement
Articles in this issue
about 25 years ago
Evaluation of Gelatins for Cross-Linking Potentialabout 25 years ago
Fast-Melting Tablets: Developments and TechnologiesAdvertisement
Related to this article
Boehringer, AbbVie, ASKA, and Evommune license ADC, IBD, thyroid eye disease, and degrader assets, raising tech transfer demands for manufacturers.
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
Vivek Gupta of Duquesne University explains at AAPS PharmSci 360 why device decisions can't wait and why excipient makers must test beyond drug molecules.
Industry subject matter experts spoke about the challenges of turning complex molecules into medicines patients can reliably use.
USP’s Sheehan and Liu talk at AAPS PharmSci 360 abou getting novel excipients past the monograph hurdle through early engagement with FDA.
Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
3
AAPS PharmSci 360: How USP Is Tackling the Novel Excipient Roadblock
4
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
5